- Home
- UGI vs ABVX Comparison
UGI vs ABVX Comparison
Compare UGI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | UGI | ABVX |
|---|---|---|
| Founded | 1940 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 9.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UGI | ABVX |
|---|---|---|
| Price | $37.09 | $119.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $44.00 | ★ $122.00 |
| AVG Volume (30 Days) | 1.9M | ★ 2.0M |
| Earning Date | 02-04-2026 | 08-11-2025 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ 147.20 | N/A |
| EPS | ★ 3.09 | N/A |
| Revenue | ★ $7,287,000,000.00 | $6,231,374.00 |
| Revenue This Year | $21.37 | $6.80 |
| Revenue Next Year | $3.03 | N/A |
| P/E Ratio | $12.04 | ★ N/A |
| Revenue Growth | ★ 1.07 | N/A |
| 52 Week Low | $28.25 | $4.77 |
| 52 Week High | $39.59 | $148.83 |
Technical Indicators
Market Signals| Indicator | UGI | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 47.24 |
| Support Level | $36.69 | $108.95 |
| Resistance Level | $37.82 | $129.64 |
| Average True Range (ATR) | 0.65 | 8.13 |
| MACD | -0.19 | -2.53 |
| Stochastic Oscillator | 24.44 | 27.08 |
Price Performance
Historical ComparisonAbout UGI UGI Corporation
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.